매크로 컨텍스트

테마

GLP-1 & Obesity Treatments

핵심 동인

  • Efpeglenatide global clinical progress
  • LAPS platform-based multiple new drug pipeline
  • GLP-1 obesity treatment market TAM of $100B
  • Technology licensing milestone receipts expected

리스크

  • Efpeglenatide Phase 3 failure risk
  • Latecomer vs. Eli Lilly/Novo Nordisk
  • Technology licensing agreement termination possibility
  • Profitability deterioration from R&D cost burden

애널리스트 컨센서스

최저 420,000 KRW최고 720,000 KRW
현재가컨센서스 목표가

2026. 6. 16. 기준

증권사애널리스트목표가투자의견
투자 기간: 12개월

모니터링 트리거

핵심 지표

  • Efpeglenatide Phase 3 progress
  • Technology licensing milestone receipt schedule
  • LAPS pipeline clinical advancement
  • R&D cost to revenue ratio

리뷰 트리거

  • Efpeglenatide interim analysis negative
  • Technology licensing agreement termination
  • Cash burn acceleration

무효화 조건

  • Efpeglenatide Phase 3 failure
  • LAPS platform technology competitiveness lost
  • GLP-1 market entry failure

노트 타임라인

진입
2026. 2. 25. · NewMoneyMoves AI

LAPS platform-based GLP-1 pipeline is the core investment thesis. Latecomer vs. Eli Lilly/Novo, but differentiated pharmacokinetic profile offers niche opportunity. Technology licensing milestones are near-term catalysts.

Related ETFs

ETFs covering the same theme as 128940.KS — alternatives when direct holding is constrained or diversification is preferred

All ETFs

Comments

생성: 2026. 2. 25.수정: 2026. 2. 25.가격 기준: 2026. 6. 16.